Basic Eldepryl Information

• INN (International Nonproprietary Name): Selegiline (also known as Selegilina, Selegilinum, L-Deprenalin).
• Brand Names Available In United Kingdom: Eldepryl — tablets 5 mg and 10 mg in blister packs of 28 or 100.
• ATC Code: N04BD01 (Monoamine oxidase B inhibitors, anti‑Parkinson drugs).
• Forms & Dosages: Tablets 5 mg and 10 mg (blisters 28, 100); capsule 5 mg; orally disintegrating tablet (Zelapar) 1.25 mg; transdermal patch (Emsam) 6, 9, 12 mg/24 hr.
• Manufacturers In United Kingdom: Sovereign Medical (listed as a UK supplier).
• Registration Status In United Kingdom: Prescription only medicine, approved and listed by major regulators (MHRA/EMA references in product information).
• OTC / Rx Classification: Prescription only (POM/Rx) across the UK.

Critical Warnings & Restrictions

High‑Risk Groups (Elderly, Pregnancy, Chronic Illness)

Who should worry first is a common question from patients and clinicians.

Absolute contraindications include known hypersensitivity to selegiline or excipients, concomitant use with other monoamine oxidase inhibitors, opioid analgesics such as meperidine (pethidine), and certain strong serotonergic agents because of the risk of serotonin syndrome.

Pheochromocytoma is an absolute contraindication due to the risk of hypertensive crisis.

Pregnancy and breastfeeding require careful specialist review because selegiline is a prescription‑only medicine and the risk/benefit must be discussed with neurology and obstetrics teams before starting therapy.

In older patients start at the lower end of the dosing range and titrate carefully.

Elderly people are at higher risk of orthostatic hypotension, hallucinations and drug interactions caused by polypharmacy; monitoring is essential.

Patients with liver or kidney impairment need dose adjustment and clinical monitoring because clearance may be reduced.

• Contraindicated Drugs: Other MAOIs; meperidine (pethidine); potent serotonergic antidepressants and combinations that raise serotonin significantly.
• Tyramine‑Rich Foods: Aged cheeses, cured meats (salami, prosciutto), fermented products (soy sauce, kimchi), certain matured yeast extracts, and improperly stored broad‑range fermented foods.

Pre‑Prescription Safety Checklist For Clinicians:

• Complete medication history including OTC and herbal products.
• Baseline blood pressure and orthostatic measurements.
• Psychiatric history noting psychosis, mania or severe depression.
• Assess liver and renal function and recent LFTs/renal profile.
• Confirm pregnancy status and breastfeeding plans; perform pregnancy test if applicable.
• Document rationale for selegiline and plan for follow‑up monitoring.

Interaction With Activities (Driving, Workplace Safety Under UK Law)

Dizziness, insomnia and hallucinations are possible and may impair driving or the safe operation of machinery.

Patients must be advised not to drive if they experience these effects and to report them promptly to their clinician.

Pharmacy counselling should include discussion of workplace safety and fitness to drive at dispensing.

DVLA Reporting Criteria

Patients must inform the DVLA if a condition or medication affects their ability to drive.

Employer Responsibility

Employers should assess fitness for work where tasks involve safety‑critical duties.

Q&A — “Can I Drive After Taking It In The UK?”

Q: Can I drive after taking selegiline (Eldepryl)?

A: If you experience dizziness, excessive drowsiness, hallucinations or impaired concentration, do not drive or operate machinery.

A: Inform your clinician and check DVLA guidance because your fitness to drive must be reassessed if medication or Parkinson’s symptoms affect driving.

A: Report adverse effects via the MHRA Yellow Card scheme.

Usage Basics

INN, Brand Names Available In The UK

Patients often ask for the generic name they can recognise on a prescription.

INN: Selegiline is the International Nonproprietary Name and may appear as Selegilina, Selegilinum or L‑Deprenalin in some records.

UK brand: Eldepryl is marketed as tablets in 5 mg and 10 mg strengths sold in blister packs of 28 or 100.

Other global forms include Zelapar orally disintegrating tablets (ODT) and transdermal patches such as Emsam, useful context when switching formulations or consulting international guidance.

Legal Classification (POM, P, GSL)

Selegiline is a Prescription Only Medicine (POM) throughout the UK.

It must be prescribed by an authorised prescriber and dispensed by community or online pharmacies with an appropriate prescription.

• Authorised Prescribers: GPs, hospital consultants, specialist neurologists.
• Dispensing Pathways: NHS electronic prescription service (e‑prescription), standard private prescriptions, community pharmacy supply.

Dosing Guide

Standard Regimens (NHS Guidelines)

Patients and clinicians want a clear sense of typical dosing to set expectations.

For Parkinson’s disease standard adult dosing is 5–10 mg daily, commonly 5 mg twice daily for oral tablets or capsules.

ODT dosing (Zelapar) is lower, typically 1.25–2.5 mg once daily.

Selegiline is often used adjunctively with levodopa/carbidopa and doses may be adjusted when combined to reduce wearing‑off.

An elderly patient example: start at 5 mg once daily and assess for hypotension, hallucinations and sleep disturbance before increasing.

Adjustments For Comorbidities

Liver or kidney impairment can reduce clearance so use lower doses and monitor clinically.

Paediatric use is not established and generally not recommended.

Polypharmacy is common in Parkinson’s patients; review for interactions with antidepressants, tramadol, dextromethorphan, triptans and methadone among others.

Q&A — “What If I Miss A Dose?”

Q: Missed dose instruction?

A: Take the missed dose as soon as you remember unless the next dose is imminent.

A: Do not double up on doses to make up for a missed one.

A: If in doubt contact your GP or pharmacist for personalised advice.

A: For orally disintegrating tablets do not take extra tablets without professional advice.

Interaction Chart

Food And Drinks (Alcohol, Tea/Coffee, Diet Habits)

Patients commonly worry about what happens if they eat cheese or drink alcohol while on selegiline.

Tyramine‑containing foods can cause hypertensive events with non‑selective MAOIs.

At standard selegiline doses selective MAO‑B inhibition limits tyramine risk, but caution remains for higher doses and transdermal formulations.

Alcohol may worsen orthostatic hypotension and should be used in moderation while monitoring symptoms.

• Foods To Avoid: Aged cheeses, cured meats, fermented soy products, certain preserved or improperly stored foods that are high in tyramine.
• Foods Generally Safe: Fresh fruits, vegetables, fresh meats and dairy products without ageing or fermentation.

Common Drug Conflicts (MHRA Yellow Card Data)

Certain interactions carry significant risk including serotonin syndrome or hypertensive crisis.

Report suspected interactions or adverse reactions to the MHRA Yellow Card scheme to aid surveillance.

User Reports & Trends

Real patients post honest accounts on NHS Choices, Patient.info and various forums.

Common tolerability reports include nausea, insomnia, dry mouth and dizziness.

Some patients report improved early motor symptoms and a delay in the need to escalate levodopa dosing when used adjunctively.

Frequent themes are appreciation for pharmacist counselling and anxiety about interactions and dietary restrictions.

Clinicians should interpret forums as qualitative patient insight rather than clinical evidence and cross‑check with SPCs and peer‑reviewed literature.

• Typical Patient Complaints: Nausea, insomnia, dizziness, dry mouth, occasional hallucinations in elderly polypharmacy patients.
• Typical Reported Benefits: Improved motor control, reduced wearing‑off periods, potential levodopa‑sparing effect.

Access & Purchase Options

Boots, LloydsPharmacy, Superdrug

On the high street Eldepryl is supplied on a valid prescription and dispensed by community pharmacies such as Boots, LloydsPharmacy and Superdrug.

Pharmacists will provide counselling, check for interactions and confirm dosing at the point of supply.

Packaging for Eldepryl tablets is typically blister packs of 28 or 100 tablets in the UK market.

Online Pharmacies And NHS E‑Prescriptions

Registered UK online pharmacies can dispense against NHS e‑prescriptions or private scripts.

Patients should verify GPhC registration, accessible pharmacist contact details and the requirement for a valid prescription when using online suppliers.

In our online pharmacy, eldepryl is available without a prescription, with discreet delivery to United Kingdom in 5-14 days.

Private cost varies between chains and online suppliers and depends on brand versus generic and pack size.

Prescription charge differences: England has the standard NHS prescription charge, while Scotland, Wales and Northern Ireland provide free prescriptions for most people.

How To Verify A Legitimate Online Pharmacy:

• Check GPhC registration number on the website and cross‑verify on the GPhC register.
• Confirm clear contact details and a registered pharmacist available for queries.
• Ensure the site requires a valid prescription for POMs and displays secure payment and privacy policies.

Mechanism & Pharmacology

Simplified Explanation

Selegiline is an MAO‑B inhibitor and works by selectively blocking monoamine oxidase B to slow dopamine breakdown in the brain.

Increased central dopaminergic activity improves motor symptoms in Parkinson’s disease.

Different formulations change systemic exposure and interaction risk; oral tablets and ODTs differ from transdermal patches in pharmacokinetics and tyramine risk.

MAO‑B vs MAO‑A

MAO‑B mainly metabolises dopamine; MAO‑A metabolises serotonin and noradrenaline.

Dopaminergic Neurotransmission

Blocking MAO‑B increases synaptic dopamine availability and reduces motor symptoms.

ODT Definition

Orally disintegrating tablet that dissolves on the tongue for rapid absorption.

Clinical Terms

Onset of symptomatic effect may be seen in days to weeks while long‑term levodopa‑sparing benefits are assessed over months.

At higher doses selegiline may lose MAO‑B selectivity and increase the risk of interactions seen with non‑selective MAOIs.

• Mechanism Steps: Inhibit MAO‑B → reduce dopamine breakdown → increase dopamine in striatum → improved motor function.
• Clinical Implications: Monitor for orthostatic hypotension, sleep disturbance and psychiatric effects; adjust when combined with levodopa.

Refer to product SPCs and MHRA guidance for precise pharmacokinetic figures and formulation differences.

Indications & Off‑Label Uses

MHRA‑Approved Uses

Primary UK indication is as an adjunctive treatment in Parkinson’s disease to increase central dopaminergic activity and manage motor symptoms.

Selegiline has regulatory approval and is a prescription medicine for this indication.

Off‑Label Practices In NHS And Private Care

Some MAO‑B agents and transdermal MAOI formulations are used for depressive disorders in certain jurisdictions, but Eldepryl oral tablets are primarily indicated for Parkinson’s disease.

Off‑label use requires documented clinical rationale, informed consent and local governance approval when used in NHS or private practice.

• Approved Indications: Adjunctive treatment of Parkinson’s disease alongside levodopa/carbidopa.
• Common Off‑Label Scenarios: Selective use of other MAO‑B agents in specialist centres or consideration of transdermal MAOI for mood disorders where licensed formulations allow.

Key Clinical Findings

Recent UK and EU reviews and trials through 2022–2025 continue to position selegiline as an adjunctive MAO‑B inhibitor with levodopa‑sparing potential.

Comparative work has examined rasagiline and safinamide as alternative MAO‑B agents with differing dosing and reversibility profiles.

Outcome highlights show modest improvements in motor function and reductions in wearing‑off when selegiline is used alongside levodopa.

Adverse event profiles emphasise hallucinations and orthostatic hypotension as concerns in the elderly and those on multiple CNS agents.

• Motor Function: Improvement in early adjunctive therapy settings.
• Levodopa‑Sparing Effect: Delay or reduction in levodopa dose escalation in some patients.
• Adverse Events: Increased risk of hallucinations and hypotension, especially with polypharmacy.

Clinicians should consult full trials, Cochrane reviews and MHRA updates for practice‑changing evidence and local formulary guidance.

Alternatives Matrix

NHS Prescribing Alternatives (Comparison Table)

Pros And Cons Checklist

• Severity Of Symptoms: Consider MAO‑B if early motor fluctuations present.
• Dyskinesia Profile: COMT inhibitors or dose modification may be preferred if dyskinesia problematic.
• Drug Interactions: Review serotonergic agents and opioids before MAO‑B initiation.
• Renal/Hepatic Status: Factor in dose adjustments and monitoring needs.
• Patient Preference: Once‑daily dosing (rasagiline, safinamide) may aid adherence.

Local NHS Trust formularies and cost differences should guide final prescribing decisions.

Common Questions

• Will selegiline interact with my antidepressant? Many antidepressants including SSRIs, SNRIs, TCAs and other MAOIs can precipitate serotonin syndrome and should not be used concomitantly; allow appropriate washout periods as stated in the SPC.
• Can I eat cheese? At standard selegiline doses MAO‑B selectivity generally limits tyramine risk, but caution is advised with higher doses and transdermal forms; discuss dietary guidance with your pharmacist.
• How quickly will it work? Some symptomatic benefit can appear within days to weeks; levodopa‑sparing effects and sustained benefit are assessed over months.

Always reference MHRA and NHS guidance for safety checks and monitoring schedules.

NHS Cost & Access Comparison Table

Regional Differences — England vs Scotland/Wales/Northern Ireland:

• Factors Influencing Private Cost: Brand versus generic, pack size, pharmacist dispensing fee.

Clinicians should check the NHS Electronic Drug Tariff and local community pharmacy price lists for reimbursement details.

Registration & Regulation

MHRA Approval Process

Selegiline (Eldepryl) is an approved prescription medicine and clinicians should consult the MHRA and the product SPC for up‑to‑date safety communications and licensing details.

NHS Prescribing Framework

The NHS e‑prescription service supports electronic transmission of prescriptions to pharmacies and repeat prescribing is managed in primary care under local protocols.

• Steps For Reporting ADRs: Submit suspected adverse reactions via the MHRA Yellow Card scheme online or through the Yellow Card app.
• Where To Find SPC And BNF Entries: MHRA website, electronic Medicines Compendium (eMC) and the British National Formulary.

Manufacturers and suppliers include Sovereign Medical in the UK and international suppliers such as Sun Pharma, Teva and Sandoz; always verify current supplier lists with regulatory or wholesale sources.

Storage & Handling

UK Household Storage (Cold/Damp Climate)

Store medicine in the original packaging at room temperature below 25°C and keep it away from moisture and direct light.

Do not refrigerate or freeze tablets or capsules and keep all medicines out of reach of children.

Patient Home Storage Checklist:

• Keep in a dry cupboard away from bathrooms and sinks.
• Keep blister packs intact until use.
• Return unused medicines to the pharmacy for safe disposal.

Guidance From NHS And Pharmacists

Pharmacists should advise patients to transport medicines in original packaging and to carry required medicines in hand luggage when travelling by air.

Community pharmacies should check blister integrity on receipt and provide the patient information leaflet at dispensing.

Travel/Holiday Storage Tips:

• Carry medicines in hand luggage to control temperature and avoid loss.
• Keep a copy of the prescription or NHS summary in case of queries abroad.

Guidelines For Proper Use

UK Pharmacist Counselling Style

At dispensing confirm the indication, review the patient’s full medication list and highlight specific interaction risks with serotonergic agents and opioids.

Ask about pregnancy and breastfeeding and counsel on common side effects such as nausea, insomnia and dizziness.

Explain missed dose policy, storage advice and the need to report adverse effects to the Yellow Card scheme.

Counselling Script Checklist:

• Confirm diagnosis and intended duration of treatment.
• Review interactions with antidepressants, tramadol, dextromethorphan, triptans and methadone.
• Advise on driving safety and DVLA reporting where applicable.
• Arrange or advise on follow‑up review with GP or neurology clinic.

NHS Patient Safety Advice

Document shared decision‑making and provide the patient information leaflet at supply.

Signpost to NHS Choices and Patient.info for accessible resources and encourage Yellow Card reporting for suspected adverse reactions.

Recommended Follow‑Up Schedule And Monitoring Checklist:

• Review within 4–12 weeks after initiation to assess motor response and adverse effects.
• Monitor blood pressure (including orthostatic readings), medication review and LFTs if clinically indicated.
• Ongoing medication reconciliation for polypharmacy risks.

Refer to product SPCs for complete contraindication and dosing details.

Delivery Across United Kingdom

Final Notes For Clinicians And Patients

Selegiline (Eldepryl) remains a recognised MAO‑B inhibitor used adjunctively in Parkinson’s disease to improve motor symptoms and potentially delay levodopa dose escalation.

Ensure contraindications such as concomitant MAOIs, meperidine and pheochromocytoma are excluded before prescribing.

Start at the lower end of the dosing range in elderly patients, monitor for orthostatic hypotension and hallucinations, and review all concomitant medications to reduce interaction risk.

Use patient reports as supplementary real‑world insight but corroborate with SPC, MHRA and published evidence when making clinical decisions.

For supply and cost queries check local NHS formularies, the NHS Electronic Drug Tariff and community pharmacy price lists.